Ken Griffin Diagnostics & Research

Citadel Advisors LLC

$505 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
NTRA Natera, Inc.	$15.7B	$289 Million 0.06% of portfolio	2,276,558	Q3 2024 Reduced 25.31%
DHR Danaher Corp	$168B	$187 Million 0.04% of portfolio	671,386	Q3 2024 Added 54,662.32%
ICLR Icon PLC	$17.4B	$167 Million 0.03% of portfolio	580,049	Q3 2024 Reduced 57.36%
TMO Thermo Fisher Scientific Inc.	$207B	$103 Million 0.02% of portfolio	166,186	Q3 2024 Reduced 83.09%
DGX Quest Diagnostics Inc	$15.6B	$103 Million 0.02% of portfolio	748,133	Q3 2024 Reduced 35.9%
TWST Twist Bioscience Corp	$2.76B	$67 Million 0.01% of portfolio	1,482,556	Q3 2024 Added 3.83%
SHC Sotera Health CO	$3.83B	$36.7 Million 0.01% of portfolio	2,201,031	Q3 2024 Added 229.56%
A Agilent Technologies, Inc.	$40.3B	$33.7 Million 0.01% of portfolio	227,066	Q3 2024 Reduced 77.12%
IQV Iqvia Holdings Inc.	$37.1B	$33 Million 0.01% of portfolio	139,517	Q3 2024 Reduced 55.44%
NEOG Neogen Corp	$2.64B	$18.9 Million 0.0% of portfolio	1,123,649	Q3 2024 Reduced 59.9%
CSTL Castle Biosciences Inc	$723M	$18.1 Million 0.0% of portfolio	633,016	Q3 2024 Reduced 8.71%
CDNA Care Dx, Inc.	$1.12B	$12.9 Million 0.0% of portfolio	411,687	Q3 2024 Added 241.65%
IDXX Idexx Laboratories Inc	$34.4B	$11.7 Million 0.0% of portfolio	23,100	Q3 2024 Reduced 70.14%
RDNT Rad Net, Inc.	$4.16B	$9.43 Million 0.0% of portfolio	135,879	Q3 2024 New
GH Guardant Health, Inc.	$3.23B	$7.58 Million 0.0% of portfolio	330,401	Q3 2024 Reduced 89.96%
FLGT Fulgent Genetics, Inc.	$560M	$6.58 Million 0.0% of portfolio	302,918	Q3 2024 Added 62.65%
MEDP Medpace Holdings, Inc.	$10.7B	$5.42 Million 0.0% of portfolio	16,252	Q3 2024 Added 68.33%
OPK Opko Health, Inc.	$1.17B	$3.73 Million 0.0% of portfolio	2,501,674	Q3 2024 Added 626.53%
CRL Charles River Laboratories International, Inc.	$9.48B	$2.8 Million 0.0% of portfolio	14,197	Q3 2024 Reduced 50.81%
ILMN Illumina, Inc.	$21.3B	$2.07 Million 0.0% of portfolio	15,842	Q3 2024 Reduced 96.28%
MYGN Myriad Genetics Inc	$1.11B	$1.86 Million 0.0% of portfolio	68,061	Q3 2024 Reduced 96.14%
EXAS Exact Sciences Corp	$10.3B	$730,000 0.0% of portfolio	10,729	Q3 2024 Reduced 97.67%
ACRS Aclaris Therapeutics, Inc.	$193M	$411,000 0.0% of portfolio	364,567	Q3 2024 Reduced 58.35%
WAT Waters Corp	$22.3B	$351,000 0.0% of portfolio	978	Q3 2024 Reduced 98.8%
NEO Neogenomics Inc	$2.08B	$283,000 0.0% of portfolio	19,226	Q3 2024 New
PSNL Personalis, Inc.	$273M	$188,000 0.0% of portfolio	34,990	Q3 2024 Reduced 90.15%
ME 23and Me Holding Co.	$834M	$165,000 0.0% of portfolio	473,971	Q3 2024 Added 277.93%
MTD Mettler Toledo International Inc	$28B	$163,000 0.0% of portfolio	109	Q3 2024 Reduced 90.61%
LAB Standard Biotools Inc.	$144M	$126,000 0.0% of portfolio	65,670	Q3 2024 Reduced 92.75%
DRIO Dario Health Corp.	$16.3M	$74,000 0.0% of portfolio	66,364	Q3 2024 Added 16.92%
XGN Exagen Inc.	$80.5M	$71,000 0.0% of portfolio	23,009	Q3 2024 Reduced 9.34%
PMD Psychemedics Corp	$10.6M	$49,000 0.0% of portfolio	21,509	Q3 2024 Added 70.17%
ENZ Enzo Biochem Inc	$36.1M	$29,000 0.0% of portfolio	26,594	Q3 2024 New
BDSX Biodesix Inc	$59.2M	$24,000 0.0% of portfolio	14,009	Q3 2024 Added 146.9%

Shares Options

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track Ken Griffin's portfolio

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account